Genmab — Januar 2018
-
https://ir.syros.com/press-releases/detail/115/syros-announces-clinical-supply-agreement-with-janssen-to Novod oplyser, at data fra dette fase 2 studie allerede vil være tilgængelige H218.
-
SY-1425 har vi tidligere fremhævet som en mulig partner til Daratumumab, idet stoffet fremmer "visningen" af CD38. Se abstract https://d1io3yog0oux5.cloudfront.net/_4ae065403993c3f6b7262fd4ef0c7669/syros/db/353/1960/pdf/201709_ESH_SY1425_FINAL.pdf , som viser klart bedre effekt end eks ATRA til at "vise" / udtrykke CD38.
-
@ROI, thanks for your comprehensive contribution. As always, a great read. I must say that if there would be a takeover within a couple months (which I believe has a reasonable probabillity) the acquisition price will be higher than 2200 dkk. JVDW indeed has always told the public 100% premium however I will be amazed if he accepts this while we already have been to +/- 1500. So 3000 minimum seems more likely to mee. At minimum!
Thanks again
1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind